Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
about
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusClosing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondImpact of sodium-glucose cotransporter 2 inhibitors on blood pressurePharmacogenomics in diabetes mellitus: insights into drug action and drug discoveryThe efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.DapagliflozinDapagliflozin for the treatment of type 2 diabetes: a review of the literatureThe efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.Short commentary on empagliflozin and its potential clinical impactEfficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusCardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Dapagliflozin: a review of its use in patients with type 2 diabetes.The effect of SGLT2 inhibitors on cardiovascular events and renal function.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.SGLT2-I in the Hospital Setting: Diabetic Ketoacidosis and Other Benefits and Concerns.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors: Benefit/Risk Balance.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.Durability of response to dapagliflozin: a review of long-term efficacy and safety.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to dateDapagliflozin for the Treatment of Type 2 Diabetes Mellitus.SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.
P2860
Q26782225-CD9B645E-8F8B-455A-9ACB-8BB520F6D5AEQ28075848-0FCB4B11-006F-40F4-92BA-4643A248377AQ28080114-5F03CF13-3393-4805-A867-71C8D2ED35D3Q28274686-D897A89B-B038-4DBD-AA10-D1612EC4D609Q30557454-52CB23C5-0B3F-4A14-8D75-6A80B915896EQ33625568-6EC33265-68A5-4513-9FFC-13DC514909D9Q34613015-C8D7FB7A-CDC1-4958-AF90-95CDE72523D3Q34710819-397F4718-6421-457D-AE1E-63CEA4DEDD81Q35141884-A886C37A-E983-4601-88AC-9E0DF093D082Q35528797-A5E5FD8D-4C7B-4B6B-A8C0-03F98F8A5894Q36207940-3E4D8F0A-DAB5-45D2-A665-E1DBCDBC8C61Q36288929-B49F9334-A8E6-4B3D-9686-5A8B5FC8FBC9Q36592820-F5A6785A-2623-4678-84FC-406AA8AD70A3Q36599869-09768FA9-9130-4FF1-BA02-3C0840F326EFQ37060855-882EB384-6D41-45DA-91A2-0D333F6A06FEQ37721962-115C0494-B4ED-4EA4-8E28-D68451C7CDC2Q37722896-42AC05D0-075F-4A8D-85D4-A8D58F3533D0Q38199526-C47000DC-BFE8-47B9-AE84-9DC57278E513Q38260353-FE657D1D-4FA5-45B5-AFC0-3B97C8F0B9A9Q38267346-FA94DFC4-161E-473E-BC97-348B0FB493FEQ38614488-0D34FA55-9744-4D10-8DEA-5173DC80E70DQ38619164-838938EB-58FE-4B74-99F5-88768E7E0A01Q38715153-72C113B0-E335-4B16-AE51-E440B7DF2C62Q38734956-7E2958AE-F9F7-432E-89A9-41BB5E5E4BC6Q38783203-B6212608-D548-4C59-B59E-0D9FFC4F7534Q38870752-14457D51-2ED0-4F90-8D05-D75D60F7313AQ38906041-ABEFC92C-5158-4EFD-97C9-381D6CD5148EQ38931842-CBAC37DC-4A0D-47A5-9E22-35F05F7D0DF0Q39170860-A8BF8597-9648-400B-9F63-72D0D5DB031AQ39189383-7368F778-F26D-4F89-96B7-D5754BF1E67BQ39355218-9232959F-34C3-4577-B517-862153AB39AFQ39430445-68405687-29F5-416D-905C-CEAADFE98664Q40068172-8AB08545-6BF6-4383-98DF-6807BE8FF287Q42373168-35EB79FF-975F-42EA-9156-EC2ABC4DA97EQ45914699-2E2AA1EC-BC34-4E16-B662-7A9E38375902Q47095186-12157C08-0ECC-45FF-9A97-6AC22457E116Q51034590-45D666B8-0CA0-4B4F-BE81-F8DD0909D614Q55411384-CC400F02-EA3E-43E2-AFD7-9321B157BF68
P2860
Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dapagliflozin treatment for ty ...... randomized controlled trials.
@ast
Dapagliflozin treatment for ty ...... randomized controlled trials.
@en
type
label
Dapagliflozin treatment for ty ...... randomized controlled trials.
@ast
Dapagliflozin treatment for ty ...... randomized controlled trials.
@en
prefLabel
Dapagliflozin treatment for ty ...... randomized controlled trials.
@ast
Dapagliflozin treatment for ty ...... randomized controlled trials.
@en
P2093
P2860
P356
P1476
Dapagliflozin treatment for ty ...... f randomized controlled trials
@en
P2093
P2860
P304
P356
10.1002/DMRR.2479
P50
P577
2014-03-01T00:00:00Z